Surgical Oncologist, Urologist
Xalmurzaev Oybek Avazxanovich
Uro-oncology
Professional summary
Uro-oncologist, MD PhD, Deputy Director for Science and Education, with 25 years of clinical and research experience. For many years a research fellow in urology at the N.N. Blokhin National Cancer Research Centre, with research and clinical training at Saarland University Medical Center in Germany, including as a DFG fellow. He specialises in complex, high-technology surgery for tumours of the genitourinary system and leads the centre's research activity; he is also scientific supervisor of the uro-oncology department. Member of the EAU.
Areas of expertise
- Open, laparoscopic and endoscopic surgery for genitourinary cancers, including high-technology and reconstructive procedures
- Surgical treatment of complex kidney cancer, including tumour thrombus of the inferior vena cava and thrombectomy
- Diagnosis and surgical treatment of penile cancer, including organ-preserving and reconstructive procedures
- Modern surgical treatment of bladder and prostate cancer
- Management of complex and locally advanced uro-oncological disease
Education & training
Second Tashkent State Medical Institute, Faculty of General Medicine (1995–2002)
Master's / clinical residency in Urology, Tashkent Medical Academy (2002–2005)
Postgraduate research in Oncology, N.I. Pirogov Russian National Research Medical University, based at the N.N. Blokhin Russian Cancer Research Centre (2010–2012)
Doctoral studies, N.N. Blokhin National Medical Research Centre of Oncology (2015)
Research fellowships, Saarland University Medical Center, Germany (2015, 2018)
Certifications & licenses
MD, PhD (Candidate of Medical Sciences). Member of the Russian Society of Onco-Urology, the European Association of Urology (EAU) and the Association of Oncologists of Russia.
Achievements & research
Candidate of Medical Sciences (PhD); author of more than 50 scientific publications and co-author of a Russian Federation patent in antitumour immunotherapy. Research interests include molecular and genetic alterations in genitourinary tumours, the tumour microenvironment and immune mechanisms, and prognostic and predictive biomarkers.